Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen

被引：12
|
作者：
Ferraldeschi, Roberta [1 ,2 ]
Howell, Sacha J. [1 ]
Thompson, Alastair M. [3 ,4 ]
Newman, William G. [5 ]
机构：
[1] Christie Hosp Natl Hlth Serv Fdn Trust, Manchester, Lancs, England
[2] Univ Manchester, St Marys Hosp, Manchester Acad Hlth Sci Ctr MAHSC, Manchester M13 0JH, Lancs, England
[3] Univ Dundee, Dundee, Scotland
[4] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Manchester, Manchester Acad Hlth Sci Ctr MAHSC, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 29期
关键词：
CANCER RECURRENCE RISK; ANTIDEPRESSANT USE; METABOLISM; GENOTYPE; WOMEN;
D O I：
10.1200/JCO.2010.30.1887
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E584 / E585
页数：2
相关论文
共 50 条
  • [1] Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen Reply
    Dezentje, Vincent O.
    van Blijderveen, Nico J. C.
    Gelderblom, Hans
    Putter, Hein
    van Herk-Sukel, Myrthe P. P.
    Casparie, Mariel K.
    Egberts, Antoine C. G.
    Nortier, Johan W. R.
    Guchelaar, Henk-Jan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : E586 - E586
  • [2] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [3] Impact of CYP2D6 inhibitors on tamoxifen metabolism in breast cancer patients
    Keller, Denise
    Medwid, Samantha
    Schwarz, Ute
    Legan, Robin
    Kim, Richard
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 250 - 253
  • [4] Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
    Zembutsu, Hitoshi
    Sasa, Mitsunori
    Kiyotani, Kazuma
    Mushiroda, Taisei
    Nakamura, Yusuke
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 185 - 193
  • [5] The ethics of CYP2D6 testing for patients considering tamoxifen
    Hartman, Anne-Renee
    Helft, Paul
    [J]. BREAST CANCER RESEARCH, 2007, 9 (02)
  • [6] The ethics of CYP2D6 testing for patients considering tamoxifen
    Anne-Renee Hartman
    Paul Helft
    [J]. Breast Cancer Research, 9
  • [7] CYP2D6 genotype and tamoxifen response
    James M Rae
    Matthew P Goetz
    Daniel F Hayes
    James N Ingle
    Lang Li
    Anna Maria Storniolo
    Vered Stearns
    David A Flockhart
    [J]. Breast Cancer Research, 7
  • [8] Tamoxifen and CYP2D6: A Contradiction of Data
    Hertz, Daniel L.
    McLeod, Howard L.
    Irvin, Dwilliam J., Jr.
    [J]. ONCOLOGIST, 2012, 17 (05): : 620 - 630
  • [9] CYP2D6 Genotype and Adjuvant Tamoxifen
    Berry, D. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 138 - 140
  • [10] CYP2D6 genotype and tamoxifen response
    Rae, JM
    Goetz, MP
    Hayes, DF
    Ingle, JN
    Li, L
    Storniolo, AM
    Stearns, V
    Flockhart, DA
    [J]. BREAST CANCER RESEARCH, 2005, 7 (05)
12345